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Introduction:
Cancer is the leading cause of deaths worldwide today, which have affected the lives of millions of people around the world. Efforts have been made towards development of new drugs for the prevention and treatment of cancer. The major problem of cancer treatment is the adverse effects of chemotherapy drugs which have been reported to have negative impact in our body and also suppression of the immune system. Besides, the effectiveness of chemotherapy is limited by drug resistance [1, 2] . There is an urgent need for new anti-cancer drugs and therapies. Plant derived natural compounds have been in use against various ailments since ancient period and has been regarded as promising drugs against cancer without much of side-effects. A total of 26 plant derived drugs were approved/launched during 2000-2006 [3] . Alkaloids such as vinblastine isolated from Catharanthus roseus, is commonly used to treat Hodgkin's lymphoma [4, 5] .
Camptothecin, another monoterpene indole alkaloid isolated from certain angiosperms have been effective against recurrent colon cancer and its cellular target is DNA topoisomerase I [6, 7] .
Paclitaxel, a diterpene alkaloid isolated from Taxus brevifolia is effective against breast and ovarian cancer and acts by blocking depolymerization of microtubules [8] . Etoposide, a semisynthetic derivative of podophyllotoxin, isolated from roots of Podophyllum peltatam has been approved for lung cancer, choriocarcinoma, ovarian cancer, lymphoma etc and its mode of action is through inhibition of DNA topoisomerase II [8] .
The rapid advancement of high throughput screening, structural elucidation and combinatorial synthesis have revitalized the potential of plant derived compounds as chemotherapeutic agents against cancer. For developing any natural product for clinical application we need to comprehensively understand and identify its molecular targets and mode of action [9] .
Computational screening programs such as molecular docking has greatly helped in rapid screening of chemical entities against their macromolecular targets [10] [11] [12] . Besides, in silico toxicity screens have routinely been employed in drug discovery pipelines to study the pharmacokinetic and pharmacodynamics properties of the selected drug-like compounds before proceeding to experimental trials [13] .
Recently, fifteen novel Himalayan plant derived compounds have been reported which display anti cancer properties [14] . The present study aims at exploring the binding modes of these fifteen compounds against nine selected molecular targets-CDK-2, CDK-6, Topoisomerase I, DNA Topoisomerase II, Telomere: G-quadruplex, Bcl-2, VEGFR-2, β-tubulin and XIAP because of their essential role in regulating cellular proliferation and apoptosis [15] . These 15 plant derived compounds belong to different classes of natural compounds. The binding modes of the docked complexes were subjected to molecular dyamics (MD) simulation in order to determine the stability of the system. MM/PBSA binding analysis was performed to determine the driving energy component for molecular interaction and binding per residue contribution.
The physicochemical properties of the compounds were determined to explore their bioavailability and possible toxicities in humans.
Materials and methods

Structure modeling of active compounds
The structural information of the fifteen selected compounds viz; Acetylshikonin (cmpd1), 5,7,4'-Trimethoxyflavanone (cmpd2), 3-(8'(Z),11'(Z)-pentadecadienyl)catechol (cmpd3), 3, 5, 6, 7, 8, 3 ',4'-heptamethoxyflavone (cmpd4), Chrysoplenetin (cmpd5), Chrysosplenol (cmpd6), 1-phenyl-hepta-1,3,5-triyne (cmpd7), Asclepin (cmpd8), 12B-hydroxycalotropin (cmpd9), Solamargine (cmpd10), Taxiresinol (cmpd11), Isotaxirenisol (cmpd12), Secoisolariciresinol (cmpd13), 2-deacetoxytaxinine J (2-DAT-J) (cmpd14) and Asiati cacid (cmpd15) reported to have anti-anticancer properties were retrieved from the review literature [14] . The 2D structures of the fifteen compounds were modeled and converted to 3D structures using ACD/ChemSketch version 12.01 software. These structures were then optimized using MMFF force field, using optimization parameters such as 500 steps of steepest descent algorithm and convergence criterion of 10e-7 [16] . The optimized structures were used for molecular docking studies.
Molecular docking studies
The three dimensional structures of nine selected molecular targets (receptors) involved in regulating cell proliferation and apoptosis-CDK-2(PDB ID: 1DI8), CDK-6(PDB ID: 1XO2), Topoisomerase I (PDB ID: 1T8I), Topoisomerase II (PDB ID: 1ZXM), G-Quadruplex (PDB ID: 1L1H) , Bcl-2(PDB ID: 2O2F), VEGFR-2 (PDB ID: 2OH4), β-Tubulin (PDB ID: 4I4T) and XIAP-Bir2 (PDB ID: 4KJU) were obtained from Protein Data Bank (PDB) (www.rcsb.org).
Because of the absence of β tubulin crystal structure in Homo sapiens we used Bos taurus tubulin as it showed 100 % identity with humans (Chain B of PDB ID: 4I4T). The steps for preparation of receptors include (a) removal of heteroatoms (water, ions), (b) addition of polar hydrogens, and (c) assignment of Kollman charges. The active sites were defined by considering grid boxes of appropriate sizes around the bound co-crystal ligands as shown in Table 1 .
The fifteen natural compounds were docked against nine molecular targets using AutoDock4.2 software [17] . Docking experiment was performed using Lamarckian Genetic Algorithm, with an initial population of 250 randomly placed individuals, a maximum number of 10 6 energy evaluations, a mutation rate of 0.02, and a crossover rate of 0.8. One hundred independent docking runs were performed for each compound. Conformation clustering was done considering root mean square deviation (RMSD) cut-off of 2.0 Å were cluster and the most favorable conformation was represented by the lowest free energy of binding (ΔG) and the lowest inhibition constant (K i ). The most favorable binding conformation was selected and evaluated for molecular interaction with their receptors using LigPlot+ version 1.4.5 software [18] . To ensure that the binding pose of the docked compound represents favorable and valid potential binding mode, the docking parameters and methods were validated by redocking the co-crystal ligand against their respective targets.
Molecular dynamics studies
The trajectories of docked complexes were analyzed through 20 ns of MD simulations using GROMACS 4.6.5 software package [19] with GROMOS96 43a1 force field for protein docked complexes and Amber ff99SB force field for DNA docked complex. The complexes were prepared for MD simulation through solvation within a water filled 3-D cube of 1 Å spacing using simple point charge (SPC216), a three-point model for water. A leap-frog time integration algorithm was used for integrating Newton's equations of motion. The systems were neutralized and energy minimized. The temperature was set at 300 K and the complexes were equilibrated for 100 ps in NVT (Number of particles, Volume and Temperature) ensemble and another 100 ps in NPT ensemble (Number of particles, Pressure and Temperature). After heating and equilibration, the docked complexes were subjected to production MD run for 20 ns in NPT ensemble. PRODRG web server [20] and ACPYPE program [21] was used to generate topologies for ligands compatible with GROMOS96 43a1 force field and Amber ff99SB force field respectively. The particulars of the docked complexes used in MD simulation are enumerated in Table 2 . Root mean square deviation (RMSD) and potential energies of the docked complexes was calculated using g_rms and g_energy programs respectively. The graphs are generated using Origin 7.0 software and Xmgrace plotting tools.
MM/PBSA binding energy analysis
The binding free energies of the docked complexes were computed using g_mmpbsa tool of GROMACS software [22] based on the molecular mechanics/Poisson-Boltzman surface area (MM/PBSA) method [23] . The binding energy of the target with the ligand in solvent (ΔG bind ) is calculated using equation (Eq. 1):
where, G complex is the total free energy of the target-ligand complex and target G and G ligand are total free energies of the target and ligand in solvent, respectively.
The free energy for each individual component can be expressed by equation (Eq. 2)
where, x is the target or ligand or target−ligand complex. The binding free energy calculations were performed for 1000 frames taken at an interval of 10 ps during the equilibrium phase of each trajectory of MD simulation. The average binding energy was computed by using bootstrap analysis method [22] .
Physicochemical profile of active compounds
The drug attrition is a serious problem at clinical stages of drug development due to lack of sufficient pharmacokinetics and pharmacodynamics studies. and PreADMET (https://preadmet.bmdrc.kr/).
Results and Discussion
Molecular docking analysis
Before proceeding with docking of selected natural compounds, the docking protocols and Table 3 . The molecular interaction of the best docked compound against each target was analyzed in detail.
Molecular interaction of cmpd15 with CDK-2
Cmpd15 was best docked with CDK-2 with binding energy of -10.96 kcal/mol and inhibition constant of 9.24 nM. It interacts with CDK-2 through four hydrogen bonds with Ile10, His84, Gln85, Leu298 and hydrophobic interactions with Ala31, Phe82, Leu83, Asp86, Lys89, Gln131
and Leu134 ( Figure 3A ). Previous report showed that extract of Centella asiatica containing Cmpd15 as active compound exhibited 95% inhibition against MCF-7 cell lines at concentration of 10µg/ml [25] and anti-proliferative effects on multiple myeloma RPMI 8226 cells with IC 50
values ranging from 53.76 to 24.88µmol/l from 12 to 48 hours respectively [26] . In our molecular docking studies, cmpd15 exhibited better binding energy and displayed stronger interaction with CDK-2 than co-crystal ligand (DTQ). CDK-2 is a critical enzyme regulating the transition of cells from G1 to S phase. The inhibition of this enzyme therefore, could lead to arrest of cell proliferation in cancer conditions.
Molecular interaction of cmpd8 with CDK-6
Cmpd8 was identified as the best docked compound against CDK-6, an enzyme which forms complex with cyclin D and controls the cell cycle progression from G1 to S phase. Cmpd8 displayed binding energy of -11.09 kcal/mol and inhibition constant of 7.48 nM. Its interaction with CDK-6 was comparatively stronger than the co-crystal ligand (FSE), and interacts through six hydrogen bonds with His100, Asp104, Lys147, Asn150 and Asp163 and hydrophobic interactions with Ile19, Gly20, Gly22, Val27, Val101, Asp102, Gln103, Gln149 and Leu152
( Figure 3B ). Earlier report showed that the isolated bioactive compound cmpd8 from Asclepias curassavica showed IC 50 of 0.02 mg/ml against human hepatoma carcinoma cell line [27] .
Molecular interaction of cmpd9 with Topoisomerase I, Topoisomerase II, Bcl-2, VEGFR-2 and XIAP-Bir2
Interestingly, cmpd9 showed best interactions with five macromolecular targets viz; This interaction was comparatively stronger than the co-crystal ligand, and encompasses three hydrogen bonds through Lys425, Tyr426 and Met428 and hydrophobic interactions via Ala351, Asn352, Ile427, Leu429, Pro431, Lys436, Lys439 and Asp440 ( Figure 3C ). Earlier report showed that the isolated bioactive compound cmpd9 from Asclepias curassavica showed IC 50 of 0.69 mg/ml against human hepatoma carcinoma cell line [27] . This compound showed strong interaction with Topoisomerase I, an enzyme which cleaves one of the strands of double stranded DNA and reanneals the strand. Cmpd9 interacts with Topoisomerase II with binding energy of - nM. The X-linked inhibitor of apoptosis protein (XIAP) belongs to IAP family and strong inhibitor of the caspase. This interaction was comparatively stronger than the co-crystal ligand, and encompasses two hydrogen bonds through Lys206 and Lys208 and hydrophobic interactions via Gln197, Leu207, Asn209, Trp210, Glu211, Asp214, Glu219, Arg222 and His223 ( Figure 3I ).
Molecular interaction of cmpd12 with G-quadruplex DNA
G-quadruplex are DNA sequences containing simple guanine-rich tandem repeats at the ends of eukaryotic chromosomes, which maintain genomic stability. Cmpd12 was best docked with Gquadruplex with binding energy of -8.18 kcal/mol and inhibition constant of 1010 nM. This interaction was comparatively stronger than the co-crystal ligand, and encompasses one hydrogen bond through Dg2012 and hydrophobic interactions via Dt1006, Dt1007, Dt1008, Dg1009 and Dg2011 ( Figure 3E ). Isotaxirenisol (cmpd12) showed inhibition against Caco-2 cell line at IC 90 of 0.251 µg/ml [28] .
Molecular interaction of cmpd4 with β-tubulin
Cmpd4 was best docked with β-tubulin with binding energy of -10.87 kcal/mol and inhibition constant of 10.69 nM. β-tubulin is a structural unit of microtubules that regulates cell growth and motility. This interaction was comparatively stronger than the co-crystal ligand, and encompasses three hydrogen bonds through Gln11 and Cys12 and hydrophobic interactions via Ala9, Gly10, Asp69, Glu71, Gly98, Ala99, Asn101, Ser140, Thr145, Gly146, Asp179, Asn206
and Tyr224 ( Figure 3H ). 
Binding Free energy analysis
To characterize the strength of interaction of best docked ligands with their targets, the binding free energies of the docked complexes were calculated using MM/PBSA methodology considering a total of thousand frames from the last 10 ns of MD production simulation trajectories as shown in Table 4 with Bcl-2 which may be attributed to decrease contribution by Van der Waals energy, electrostatic energy and SASA non-polar solvation energy.
Residue wise contribution analysis of the docked complexes
The binding energies of the docked complexes were decomposed to explore residue wise contribution to the binding energy ( Figure 7 and Table 5 ). In the CDK-2/cmpd15 complex, the residues dominantly contributing to the binding energy include Arg214, Arg217, Lys237, Arg200, Lys242, Arg169, Arg245, Arg199, Arg274, Lys178 and Lys88. These contributing polar charged residues substantiates that electrostatic energy component is the driving component of interaction of cmpd15 with CDK-2.
In the CDK-6/cmpd8, residues contributing significantly to the binding energy include Ile19, Glu61, Leu152, Asn150, Asp102, Gln149 and Glu99. The residues Ile19, Leu152, Asn150, Asp102 and Gln149 besides higher contribution are also involved in molecular interaction with cmpd8 as revealed by our molecular docking results.
In the Topoisomerase I/cmpd9, residues contributing to the binding energy include Lys443, Lys439, Met428, Lys425 and Pro431. The residues Lys439, Met428, Lys425 and Pro431 also are involved in molecular interaction with cmpd9 corroborating with the molecular docking results.
In the Topoisomerase II/cmpd9, residues contributing to the binding energy include Ser149, Ile141, Arg162, Ile125 and Val137. The residues Ser149, Ile141, Arg162 and Ile125 are also involved in molecular interaction with cmpd9 which is in agreement with molecular docking results.
In the G-quadruplex/cmpd12 complex, nucleotides contributing to the binding energy include Dt1007, Dg2012, Dg1009, Dt1008, Dg2011, Dt1006 and Dg1010. The nucleotides Dt1007, Dg2012, Dg1009, Dt1008, Dg2011, Dt1006 and Dg1010 are also involved in molecular interaction with cmpd12.
In the Bcl-2/cmpd9 complex, residues contributing to the binding energy include Tyr199, Tyr105, Phe101, Leu198 and Asp100. The residues Tyr199, Tyr105, Phe101 and Asp100 are also involved in molecular interaction with cmpd9.
In the VEGFR-2/cmpd9complex, residues contributing to binding energy include Phe1045, Phe916, Leu838, Tyr1057, Val914, Cys1043, Val897, Leu1033 and Phe919. The residues Phe1045, Phe916, Leu838, Val914, Cys1043, Val897 and Leu1033 are also involved in molecular interaction with cmpd9.
In the β-tubulin/cmpd4 complex, residues contributing to binding energy include Tyr224, Gly142, Cys12, Gly143 and Gln11. The residues Tyr224, Cys12 and Gln11 are also involved in molecular interaction with cmpd9 as indicated before by molecular docking results.
In the XIAP-Bir2/cmpd9 complex, residues contributing to the binding energy include Asn209, Phe224, Lys208, Leu207 and His223. Interestingly, Asn209, Lys208, Leu207 and His223 are also residues involved in interaction with cmpd9 as revealed by molecular docking studies.
Analysis of physicochemical properties
The physicochemical properties and ADMET properties of fifteen compounds were analyzed using various in silico tools realizing the drug attrition rate at later stages of drug development process. The Molinspiration results show that out of fifteen natural compounds selected in our studies, five compounds did not conform to Lipinski's rule of five and exhibit various degrees of violations (Table 6 ). Lipinski's rule of five (ROF) [32] that most of the compounds except cmpd3, cmpd4, cmpd8, cmpd10, cmpd14, cmpd15 were found to be non-inhibitor of P-glycoprotein (Pgb). P-glycoprotein is a member of ATP-binding cassette superfamily of membrane transport proteins responsible for efflux of many drugs and is a major component of BBB.
Thus, the physicochemical profile study showed that the best docked compounds-cmpd4, cmpd12 and cmpd15 do not violate ROF except cmpd8 and cmpd9 which showed only one ROF violation, which is acceptable for oral bioavailability. Besides conforming to ROF, they also seem to be non-mutagenic, non-irritant, non-tumorigenic and without any adverse effects on the reproductive effect. They also seem to have good oral bioavailability, non inducer of phospholipidosis, least BBB penetrability and well human intestinal absorption. They are likely to be non CYP_2C19 inhibitor except for compounds-cmpd4 and cmpd12. But, they were found to be Pgp inhibitor except cmpd9 and cmpd12. Except for cmpd12 and cmpd15, others are likely to be weakly bound to plasma proteins. However, these physicochemical properties can be improved by structural modifications using structure activity relationship approach.
Conclusion
Realizing the potential of plant derived compounds to develop as drugs against cancer, inhibition. The present study has great relevance in area of rational drug design such as target fishing for novel compounds and drug optimization for improving their target selectivity and oral bioavailability.
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